Calcitonin
Tóm tắt
Calcitonin is a 32-amino acid polypeptide secreted by the parafollicular cells of the thyroid. Effects on bone include inhibition of osteoclasts, thus preventing bone resorption, as well as increased renal calcium excretion. Salmon calcitonin is often used therapeutically because it is more potent and has a longer duration of action compared with human calcitonin. Calcitonin also possesses analgesic properties. The mechanism of its analgesic effect is unknown but is thought to involve inhibition of prostaglandins and stimulation of β-endorphins. Most of the clinical data in postmenopausal osteoporosis involves the use of salmon calciton in nasal spray. Clinical trials have demonstrated a reduction in the risk of vertebral fractures and increased bone mineral density. Studies examining nonvertebral fractures have shown mixed results, some indicating a nonsignificant risk In general, calcitonin is inferior to bisphosphonates (BPs) in reducing fracture risk. Calcitonin is effective in the treatment of osteopathic pain. It has also been used in glucocorticoid-induced osteoporosis. Parenteral calcitonin is generally associated with more frequent side effects compared with intranasal calcitonin. Injectable administration can cause flushing, tingling, nausea, and injection site and allergic reactions. Side effects with intranasal use are usually limited to local effects (nasal congestion and irritation). Recent phase I trials with a new oral dosage form show promise in terms of efficacy and tolerability for treating patients who prefer this route of administration. This review of pertinent literature on calcitonin indicates that this remains a viable, though second-or third-line, agent for osteoporotic patients who refuse or cannot tolerate other treatments (e.g., BPs, raloxifene, and estrogen).
Tài liệu tham khảo
Carstens JH, Jr., Feinblatt JD. 1991 Future horizons for calcitonin: a U.S. perspective. Caleif Tissue Int 49(Suppl 2):S2-S6.
Singer FR. 1991 Clinical efficacy of salmon calcitonin in Pager's disease of bone. Calcif Tissue Int 49(Suppl 2):S7-S8.
Hodgson SF, Watts NB, Bilezikian JP, et al. 2001 American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 7:293–312.
Plosker GL, McTavish D. 1996 Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8:378–400.
Eastell R. 1998 Treatment of postmenopausal osteoporosis. N Engl J Med 338:736–746.
2004 Miacalcin (Calcitonin-Salmon) Nasal Spray product information. Novartis Pharmaceuticals Corporation, East Hanover, NJ: July 2003.
Silverman SL. 2003 Calcitonin. Endocrinol Metab Clin North Am 32:273–284.
Chin CM, Gutierrez M, Still JG, Kosutic G. 2004 Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy 24:994–1001.
Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M. 2002 Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17:1478–1485.
Micromedex Healthcare Series online. Calcitonins. Available at www.micormedex.com/products/drugdex. Accessed on August 31, 2004.
AUTHOR NAME 2004 Drug Facts and Comparison. Facts and Comparisons. Kastrup EK, ed. St. Louis, MO, pp. 356–357.
Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. 1991 Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344–349.
Passiu G, Bocchetta A, Martinelli V, Garau P, Del Zompo M, Mathieu A. 1998 Calcitonin in decreases lithium plasma levels in man. Preliminary report. Int J Clin Pharmacol Res 18:179–181.
Calcitonin. Available at www.drugstore com. Accessed on August 31, 2004.
Hodgson SF, Watts NB, Bilezikian JP, et al. 2003 American Association of Clinical Endocrinologists medical guide-lines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564.
Unigene Receives FDA Approval Letter for Its Nasal Calcitonin Osteoporosis Product 2004. Available at www.unigene.com. Accessed on March 1, 2004.
Nobex and Elan initiate phase I clinical trial of oratonin to treat osteoporosis 2004. Available at www.nobexcorp.com. Accessed on August 27, 2004.
Tanko LB, Bagger YZ, Alexandersen P, et al. 2004 Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538.
Ettinger MP. 2003 Aging bone and osteoporosis: strategies for preventing fracture in the elderly. Arch Intern Med 163:2237–2246.
South-Paul JE. 2000 Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Physician 63:1121–1128.
Takahash S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD. 1995 Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167–171.
Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT, Jr., Bloch KJ 1972 An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2338.
Brown JP, Josse RG. 2002 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 167:S1–34.
Cranney A, Tugwell P, Zytaruk N, et al. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23:540–551.
Kanis JA, McCloskey EV. 1999 Effect of calcitonin on vertebral and other fractures. Q J Med 92:143–149.
Cardona JM, Pastor E 1997 Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporos Int 7:165–174.
Pouilles JM, Tremollieres F, Ribot C. 1995 Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res 10:1531–1536.
Gennari C, Chierichetti S, Bigazzi S, et al. 1985 Comparative effects on bone mineral content of calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–462.
Hizmetli S, Elden H, Kaptanoglu E, Nacitarhan V, Kocagil S. 1998 The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis. Int J Clin Pract 52:453–455.
Overgaard K, Hansen MA, Jensen SB, Christiansen C. 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556–561.
Chestnut CH, III, Silverman S, Andriano K, et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group, Am J Med 109:267–276.
Lippuner K. 2003 Medical treatment of vertebral osteoporosis. Eur Spine J 12(Suppl 2):S132-S141.
Cummings SR, Chapurlat RD. 2000 What PROOF proves about calcitonin and clinical trials. Am J Med 109:330–331.
Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez DB. 1995 Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181–185.
Watts NB, Worley K, Solis A, Doyle J, Sheer R. 2004 Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manage Care Pharm 10:142–151.
Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH. 1996 Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 18:207–212.
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. 1989 Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 30:435–442.
Reginster JY, Meurmans L, Deroisy R, et al. 1994 A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 24:565–569.
Dursun N, Dursun E, Yalcin S. 2001 Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 55:505–509.
Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD. 1997 Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int 7:29–35.
Downs RW, Jr., Bell NH, Ettinger MP, et al. 2000 Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85:1783–1788.
Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. 2001 Cost effectiveness of nasal calcitonin in postmenpausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19:565–575.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795.
Gennari C, Seeman E. 2001 The First International Conference on Osteoporosis in Men, Siena, Italy, February 23–25, 2001. Calcif Tissue Int 69:177–178.
Olszynski WP, Shawn DK, Adachi JD, et al. 2004 Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26:15–28.
Eastell R, Boyle IT, Compston J, et al. 1998 Management of male osteoporosis: report of the UK Consensus Group. QJM 91:71–92.
Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E. 2002 A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521–527.
Montemurre L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. 1991 Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 49:71–76.
Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. 1995 Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 57:15–19.
Lyritis GP, Tsakalakos N, Magiasis B, Karachlios T, Yiatzides A, Tsekoura M. 1991 Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind plecebo-controlled clinical study. Calcif Tissue Int 49:369–372.
Gennari C, Agnusdei D, Camporeale A. 1991 Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49(Suppl 2):S9-S13.
Silveman SL, Azria M. 2002 The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858–867.
Ringe JD. 1989 Glucocorticoid-induced osteoporosis. Clin Rheumatol 8(Suppl 2):109–115.
Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. 1988 Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 5:99–103.
Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. 1999 Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis 142: 104–107.
Sambrook P, Birmingham J, Kelly P, et al. 1993 Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752.
The North American Menopause Society. 2002 Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 9:84–101.
National Osteoporosis Foundation. Physician's Guide to prevention and treatment of osteoporosis 2004. Available at www.nof.org. Accessed on April 8, 2004.
Martens MG. 2003 Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. J Reprod Med 48:425–434.
Hauselmann HJ, Rizzoli R. 2002 A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14:2–12.
Cramney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578.
Stumpf JL. 1989 Pharmacologic management of Paget's disease. Clin Pharm 8:485–495.
Schaiff RA, Hall TG, Bar RS. 1989 Medical treatment of hypercalcemia. Clin Pharm 8:108–121.
Szendroi M, Antal I, Liszka G, Konya A. 1992 Calcitonin therapy of aneurysmal bone cysts. J Cancer Res Clin Oncol 119:61–65.
Hamamci N, Dursun E, Ural C, Cakci A. 1996 Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Br J Clin Pract 50:373–375.
de Lange J, Rosenberg AJ, van den Akker HP, Koole R, Wirds JJ, van den BH. 1999 Treatment of central giant cell granuloma of the jaw with calcitonin. Int J Oral Maxillofac Surg 28:372–376.
Torring O, Bucht E, Sjostedt U, Sjoberg HE. 1991 Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 12:311–316.
Micieli G, Cavallini A, Martignoni E, Covelli V, Pachinetti F, Nappi G. 1988 Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment. Headache 28:196–200.
Nishi Y, Hamamoto K, Kajiyama M, Ono H, Kihara M, Jinno K. 1992 Effect of long-term calcitonin therapy by injection and nasal spray on the incidence of fractures in osteogenesis imperfecta. J Pediatr 121:477–480.
Mazzuoli GF, Tabolli S, Bigi F, et al. 1990 Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int 47:209–214.
Mystakidou K, Befon S, Hondros K, Kouskouni E, Vlahos L. 1999 Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. J Pain Symptom Manage 18:323–330.
Jaeger H, Maier C. 1992 Calcitonin in phantom limb pain: a double-blind study. Pain 48:21–27.
Reginster JY, Franchimont P. 1985 Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 3:155–157.
Chestnut CH, III. 1993 Calcitonin in the prevention and treatment of osteoporosis. Osteoporos Int 3 Suppl 1:206–207.